News | October 02, 2014

ReFlow Gains CE Mark, Initial Clinical Use of the Wingman35 Crossing Catheter and SpeX Shapeable Support Catheter

ReFlow CE Mark Wingman35 Crossing Catheter SpeX Shapeable Support Catheter

October 2, 2014 — ReFlow Medical Inc. announced the initial clinical use of its Wingman35 Crossing Catheter and speX Shapeable Support Catheter by Dr. Andrej Schmidt at University Leipzig, Germany. The devices were recently granted European Union CE mark approval for use in the peripheral vasculature. The new Wingman35 Crossing Catheter allows the physician to use their 0.035-inch guidewire of choice during procedures, and the new speX Shapeable Support Catheter provides physicians with a shapeable tip option to meet their specific case needs.

“Building on the Wingman14 design, the addition of the Wingman35 to the portfolio now expands the choice of wire I can use when treating my patients,” Schmidt said. “The unique extendable bevel tip gives me the ability to utilize the Wingman as a daily support catheter with the added benefit of crossing lesions when needed. The speX shapeable catheter further expands my capabilities with the Wingman14 device because it retains its shape and allows me to reshape as needed. I can rapidly adjust to the specific needs of each case and each patient, with predictable results.”

ReFlow Medical President and CEO, Isa Rizk, commented, “The addition of these new devices expands on our current 0.014-inch offering and builds a broad suite of products that give the physicians more options when treating a wide variety of lesions. We are thankful for the input from our scientific advisory board — we worked closely with them to develop these products. We look forward to continue to change the rules for vascular access by introducing additional products in the near term that meet the need for simple, yet effective solutions.”

ReFlow Medical has submitted applications to the U.S. Food and Drug Administration (FDA) for 510(k) clearance of both devices, which are currently under review.

For more information, please visit www.reflowmedical.com

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters| August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Overlay Init